KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Deferred Revenue: 2020-2025

Historic Current Deferred Revenue for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $47.4 million.

  • Recursion Pharmaceuticals' Current Deferred Revenue fell 4.47% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.4 million, marking a year-over-year decrease of 4.47%. This contributed to the annual value of $61.8 million for FY2024, which is 69.57% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $47.4 million for Q3 2025, which was up 19.33% from $39.7 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Current Deferred Revenue ranged from a high of $73.1 million in Q2 2023 and a low of $10.0 million during Q1 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Current Deferred Revenue had a median value of $44.0 million in 2023 and averaged $47.1 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Current Deferred Revenue surged by 537.81% in 2022, and later plummeted by 55.95% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $10.0 million in 2021, then spiked by 467.26% to $56.7 million in 2022, then tumbled by 35.79% to $36.4 million in 2023, then spiked by 69.57% to $61.8 million in 2024, then fell by 4.47% to $47.4 million in 2025.
  • Its Current Deferred Revenue was $47.4 million in Q3 2025, compared to $39.7 million in Q2 2025 and $39.7 million in Q1 2025.